LAM Von, one of our strategic advisors, has over 19 years of experience in technology venture, growth and late-stage private equity, corporate development, special situations, and public market investing. Since 2011, Mr. Lam has been the founder and managing partner at Falcon Partners, a technology investment firm based in Hong Kong and Shanghai that seeks to partner with exceptional management teams building enduring, category-defining businesses by providing patient, long-term capital. Mr. Lam invests in global software, consumer and financial technology companies with a strong China nexus, helping seed-stage companies evolve into unicorns and late-stage growth companies dynamically scale through supportive strategic capital for acquisitions, research and development and new market access. Previously, from July 2007 to March 2011, Mr. Lam managed technology private equity and public market investments as an early, senior member at Clearlake Capital, a $35 billion private equity and credit investment firm. Prior to Clearlake Capital, Mr. Lam was a private equity investor with Warburg Pincus from July 2005 to June 2007, where he executed leveraged buyout, private investment in public equity, growth equity and venture capital investments in the US, Europe and Asia. Prior to Warburg Pincus, from December 2003 to June 2005, Mr. Lam was a member of the corporate development group at Microsoft where he worked with senior management to execute acquisitions and investments for the company in the US and China. Mr. Lam started his career at JPMorgan in investment banking in August 2002.
CHEN Jeff Hungche, one of our strategic advisors, has spent over 15 years advising leading internet and technology companies in China and Asia on capital markets, technology and business development strategies. He recently rejoined China’s largest digital medical service platform WeDoctor as chief strategy officer in January 2021, a position he previously held from November 2017 to February 2019, overseeing WeDoctor’s strategy, capital markets activities, strategic investment and cooperation, and international business expansion. Prior to his current tenure at WeDoctor, Mr. Chen served as the group chief innovation officer of Fullerton Health from February 2019 to December 2020. From November 2016 to November 2017, Mr. Chen was the Head of Technology Investment Banking for Asia Pacific at HSBC, where he oversaw the firm’s TMT transactions across the region and successfully secured key mandates from leading tech companies such as China’s Ant Financial, Baidu, and Hong-Kong-listed semiconductor equipment manufacturer ASM Pacific. Before HSBC, he was a senior director with Credit Suisse Hong Kong’s TMT investment banking team from May 2011 to September 2016, focusing his coverage focused on capital raising for internet companies and traditional technology M&A transactions across APAC.
TO Man Chau, one of our strategic advisors, has spent over two decades in private equity and strategic investment, as well as cross-border M&A deals, with focus on fintech, insurtech, blockchain, TMT and digital health. In February 2021, Mr. To joined HK Bio-rhythm R&D Company Limited, a biomedical technology company based in Hong Kong focusing on home-based critical illness early detection, and is currently its chief strategy officer. Prior to this, he held various senior investment positions in the private equity divisions of leading Chinese conglomerates, including China Fosun Group from February 2017 to November 2019 and China PingAn Insurance from February 2015 to December 2016. Before joining the Chinese groups, he was the director of corporate finance in South China Capital from November 2009 to January 2015. Prior to that, he was vice president in the Deutsche Bank principal investment team under the global credit trading arm from January 2006 to November 2009, focusing on investment in pre-IPO companies. Prior to Deutsche Bank, he was a strategic development manager at Zurich Financial Services from August 2002 to August 2005, assisting in the acquisition of insurance companies in China and the rest of Asia. He started his career as a consultant at KPMG Consulting from August 1998 to August 2002. Mr. To is an associate member of Chartered Institute of Management Accountant (CIMA).
LIM Derek, one of our strategic advisors, has served as the chief investment officer and executive director of First Eagle Capital Management Pte Ltd (“FECM”), a Singapore-based firm which manages investments for the Lim familiy, since 2021. Prior to joining FECM, Mr. Lim worked at CIMB Investment Bank Berhad (“CIMB”) from 2003 to 2020 in various senior roles including as a managing director in charge of the executive committee investment portfolio in the group chief executive officer’s office. His last role was head of Asia equity capital markets and syndicate where he led teams that advised on many significant transactions. During his time at CIMB, Mr. Lim led equity market transactions that raised over $100 billion in gross proceeds. He was a member of CIMB’s investment banking management committee and CIMB’s group underwriting risk committee. Mr. Lim worked at Citigroup prior to joining CIMB.
WONG Kon Man Jason, one of our strategic advisors, is chairman to Norwich Investment Limited, which sponsored a NASDAQ-listed special purpose acquisition company Tottenham Acquisition I Limited, that later merged with Clene Nanomedicine, Inc. in December 2020. He is also the chairman to Ace Global Investment Limited, which sponsored a NASDAQ-listed special purpose acquisition company Ace Global Acquisition Limited. Mr. Wong currently also serves as independent director to two companies listed in Hong Kong, Shinsun Holdings (Group) Co Ltd (HKEX:2599) and Bamboos Health Care Holdings Ltd (HKEX:2293). He has over 25 years of capital markets investment experience in Asia Pacific, as well as a background in audit, accounting, and financial advisory. He is a founding partner and investment committee member of Whiz Partners Asia Ltd. Whiz Asia is a private equity fund formed by the ex-senior management of Transpac Capital and Nomura Securities of Japan. Whiz Partners is a fund dedicated to investing in small and medium-sized technology companies in China and Japan, with investors such as the Japanese government fund SMRJ (Organization for Small & Medium Enterprises and Regional Innovation, JAPAN), regional banks and insurance companies. Prior to this, he was a financial advisor at Transpac Capital Ltd., one of the oldest and largest venture capital firms in Southeast Asia, with investments in over 200 companies. He began his career with auditing, first joining Clay and Co. CPA and then moved on to becoming a senior auditor at Ernst & Young.